Sarofim Equity Correlations

SRFMX Fund  USD 14.43  0.01  0.07%   
The current 90-days correlation between Sarofim Equity and Invesco Global Health is 0.04 (i.e., Significant diversification). The correlation of Sarofim Equity is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Sarofim Equity Correlation With Market

Significant diversification

The correlation between Sarofim Equity and DJI is 0.05 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sarofim Equity and DJI in the same portfolio, assuming nothing else is changed.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarofim Equity. Also, note that the market value of any mutual fund could be closely tied with the direction of predictive economic indicators such as signals in population.

Moving against Sarofim Mutual Fund

  0.83ENGRX Vest Large CapPairCorr
  0.77PSHAX Short Term FundPairCorr
  0.74EIBLX Eaton Vance FloatingPairCorr
  0.74CUSDX Six Circles UltraPairCorr
  0.65SWSFX Ultra Short FixedPairCorr
  0.33PUBAX Pimco Unconstrained BondPairCorr
  0.33VTCAX Vanguard TelecommunicatioPairCorr
  0.7LGRAX Lord Abbett InvestmentPairCorr
  0.58PSTIX Stocksplus Tr ShortPairCorr
  0.47MKEFX Blackrock Eurofund ClassPairCorr
  0.31EIHIX Eaton Vance HighPairCorr

Related Correlations Analysis

Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Risk-Adjusted Indicators

There is a big difference between Sarofim Mutual Fund performing well and Sarofim Equity Mutual Fund doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sarofim Equity's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.